avutometinib (VS-6766) and defactinib

DRUG2 trials

Sponsors

Verastem, Inc.

Conditions

KRAS Activating MutationLow Grade Ovarian Serous AdenocarcinomaNon Small Cell Lung CancerOvarian Cancer

Phase 2

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

CompletedNCT04620330

Verastem, Inc.KRAS Activating Mutation, Non Small Cell Lung Cancer

Start: 2020-12-31End: 2023-12-12Updated: 2024-01-12

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Active, not recruitingNCT04625270

Verastem, Inc.Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer

Start: 2020-12-21End: 2026-12-31Target: 225Updated: 2025-01-29

Related Papers

Abstract 6368: Correlative preclinical studies to elucidate mechanisms of synergy of the combination of the RAF/MEK clamp avutometinib and the FAK inhibitor defactinib in low grade serous ovarian cancer

Cancer Research2025-04-21

Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.

2024-03-1514 citations

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Journal of Clinical Oncology2023-06-0134 citations

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced <i>KRAS</i> G12V mutant non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-017 citations

Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer

Cancer Research2023-04-04

Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Cancer Research2022-06-151 citations

ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

Journal of Clinical Oncology2022-06-018 citations

A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2022-06-014 citations

Abstract P048: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)

Molecular Cancer Therapeutics2021-12-012 citations

Abstract P121: Dual RAF/MEK inhibitor VS-6766 for treatment of solid tumors with diverse MAPK pathway alterations

Molecular Cancer Therapeutics2021-12-011 citations

Abstract P046: ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)

Molecular Cancer Therapeutics2021-12-011 citations

Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Cancer Research2021-07-019 citations

Abstract 1425: Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumors

Cancer Research2021-07-012 citations

ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

Journal of Clinical Oncology2021-05-205 citations